Stem Cell Therapeutic and Research Reauthorization Act of 2025
The source supplies the latest action, but no lifecycle stage.
Latest action (21 Jul 2026): Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
What this bill does
H.R. 5160 would reauthorize and update federal programs related to stem cell and cord blood transplantation. It extends funding for the C.W. Bill Young Cell Transplantation Program, authorizing $33,009,000 annually for fiscal years 2027 through 2031, in addition to the previously authorized $31,009,000. It also amends the Stem Cell Therapeutic and Research Act of 2005 to change how the National Cord Blood Inventory is managed: rather than setting a fixed numeric target of 150,000 new cord blood units, the bill directs the Secretary of Health and Human Services to maintain a "sufficient supply" of high-quality units, as determined by the Secretary. It gives the Secretary authority to transfer units from cord blood banks that become non-operational or fail to meet standards, to manage inventory size and composition based on clinical utility and genetic diversity, and to set contract terms based on current scientific evidence. Funding authorization for the cord blood inventory program is extended through fiscal years 2027–2031.
The bill primarily affects the federal agencies administering these programs (including HHS), qualified cord blood banks and transplant centers, and patients who rely on cord blood and stem cell transplants for treatment of certain diseases.
The bill was introduced in September 2025 by Rep. Christopher Smith and passed the House on July 20, 2026, by voice vote under a suspension of the rules, with an amendment. It now goes to the Senate for consideration; it would need to pass the Senate and be signed by the President before becoming law.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
Stem Cell Therapeutic and Research Reauthorization Act of 2025
This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).
The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research.
Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
Timeline
21 Jul 2026
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
Common questions
- What does H.R. 5160 do?
- H.R. 5160 would reauthorize and update federal programs related to stem cell and cord blood transplantation. It extends funding for the C.W. Bill Young Cell Transplantation Program, authorizing $33,009,000 annually for fiscal years 2027 through 2031, in addition to the previously authorized $31,009,000. It also amends the Stem Cell Therapeutic and Research Act of 2005 to change how the National Cord Blood Inventory is managed: rather than setting a fixed numeric target of 150,000 new cord blood units, the bill directs the Secretary of Health and Human Services to maintain a "sufficient supply" of high-quality units, as determined by the Secretary. It gives the Secretary authority to transfer units from cord blood banks that become non-operational or fail to meet standards, to manage inventory size and composition based on clinical utility and genetic diversity, and to set contract terms based on current scientific evidence. Funding authorization for the cord blood inventory program is extended through fiscal years 2027–2031. The bill primarily affects the federal agencies administering these programs (including HHS), qualified cord blood banks and transplant centers, and patients who rely on cord blood and stem cell transplants for treatment of certain diseases. The bill was introduced in September 2025 by Rep. Christopher Smith and passed the House on July 20, 2026, by voice vote under a suspension of the rules, with an amendment. It now goes to the Senate for consideration; it would need to pass the Senate and be signed by the President before becoming law.
- Has H.R. 5160 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 5160. Check the latest action and official source below.
- Who sponsored H.R. 5160?
- H.R. 5160 was sponsored by Rep. Smith, Christopher H. [R-NJ-4] (R-NJ), with 21 cosponsors.
- What's the latest action on H.R. 5160?
- Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464. (21 Jul 2026).
Related bills in Health
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Choices for Increased Mobility Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Rep. Smith, Christopher H. [R-NJ-4]
Stop China’s Exploitation of Congolese Children and Adult Forced Labor through Cobalt Mining Act
No PRC Seafood in Congress Act
Stop Support for UNRWA Act of 2026
To reauthorize the Kay Hagan Tick Act, and for other purposes.
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.